Dong-A to receive additional royalty payments over biosimilar drug

Published: 2012-01-18 06:58:00

Updated: 2012-01-18 06:58:00

Dong-A Pharmaceutical Co. is expected to receive additional royalty of its biosimilar drug (Japanese code name: FSK-0808) to treat neutropenia from its partner Gene Techno Science (GTS) in Japan.

GTC’s sublicensees Fuji Pharmaceutical and Mochida Pharmaceutical filed the license application for FSK-0808 in Japan, Dong-A officials said Monday.

Dong-A signed an agreement with GTS to transfe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.